A camelid anti-PrP antibody abrogates PrPSc replication in prion-permissive neuroblastoma cell lines

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Jones, Daryl Rhys ^a   Taylor, William Alexander ^a   Bate, Clive ^a   David, Monique ^b   Tayebi, Mourad ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b Multiple Sclerosis Research Center of New York Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIIDIOTYPIC ANTIBODY; PEPTIDE; PRION PROTEIN; RECOMBINANT PROTEIN;

ADSORPTION; ANIMAL; ARTICLE; CAMEL; CHEMISTRY; IMMUNOTHERAPY; MALE; METABOLISM; METHODOLOGY; MOUSE; NEUROBLASTOMA; NICK END LABELING; TUMOR CELL LINE;

ADSORPTION; ANIMALS; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; CAMELS; CELL LINE, TUMOR; IMMUNOTHERAPY; IN SITU NICK-END LABELING; MALE; MICE; NEUROBLASTOMA; PEPTIDES; PRPSC PROTEINS; RECOMBINANT PROTEINS;

EID: 78650069813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009804     Document Type: Article

References (49)

1. Prusiner SB (1994) Biology and Genetics of Prion Diseases. Annual Review of Microbiology 48: 655-686.
2. Prusiner SB (1998) Prions. Proceedings of the National Academy of Sciences of the United States of America 95: 13363-13383.
3. Tayebi M, Bate C, Hawke S, Williams A (2007) A role for B lymphocytes in antiinfective prion therapies? Expert Review of Anti-infective Therapy 5: 631-638.
4. Harris DA (1999) Cellular Biology of Prion Diseases. Clin Microbiol Rev 12: 429-444.
5. Diringer H, Ehlers B (1991) Chemoprophylaxis of scrapie in mice. J Gen Virol 72 (Pt 2): 457-460.
6. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, et al. (2002) Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A 99: 10849-10854.
7. Caughey B, Ernst D, Race RE (1993) Congo red inhibition of scrapie agent replication. J Virol 67: 6270-6272.
8. Adjou KT, Privat N, Demart S, Deslys JP, Seman M, et al. (2000) MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters. J Comp Pathol 122: 3-8.
9. Korth C, May BC, Cohen FE, Prusiner SB (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 98: 9836-9841.
10. Adjou KT, Demaimay R, Lasmezas C, Deslys JP, Seman M, et al. (1995) MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob Agents Chemother 39: 2810-2812.
11. Beringue V, Vilette D, Mallinson G, Archer F, Kaisar M, et al. (2004) PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. J Biol Chem 279: 39671-39676.
12. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, et al. (2001) Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412: 739-743.
13. Enari M, Flechsig E, Weissmann C (2001) Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 98: 9295-9299.
14. White AR, Enever P, Tayebi M, Mushens R, Linehan J, et al. (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422: 80-83.
15. Tayebi M, Hawke S (2006) Antibody-mediated neuronal apoptosis: therapeutic implications for prion diseases. Immunol Lett 105: 123-126.
16. Pilon J, Loiacono C, Okeson D, Lund S, Vercauteren K, et al. (2007) Anti-prion activity generated by a novel vaccine formulation. Neurosci Lett 429: 161-164.
17. Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ (2008) CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 16: 481-486.
18. Song CH, Furuoka H, Kim CL, Ogino M, Suzuki A, et al. (2008) Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J Gen Virol 89: 1533-1544.
19. Campana V, Zentilin L, Mirabile I, Kranjc A, Casanova P, et al. (2009) Development of antibody fragments for immunotherapy of prion diseases. Biochem J 418: 507-515.
20. Tayebi M, Collinge J, Hawke S (2009) Unswitched immunoglobulin M response prolongs mouse survival in prion disease. J Gen Virol 90: 777-782.
21. Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, et al. (2001) Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294: 178-182.
22. Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, et al. (2002) Immunization delays the onset of prion disease in mice. Am J Pathol 161: 13-17.
23. Schwarz A, Kratke O, Burwinkel M, Riemer C, Schultz J, et al. (2003) Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 350: 187-189.
24. Goni F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, et al. (2005) Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133: 413-421.
25. Goni F, Prelli F, Schreiber F, Scholtzova H, Chung E, et al. (2008) High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 153: 679-686.
26. Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, et al. (2004) Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303: 1514-1516.
27. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, et al. (2003) A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 9: 893-899.
28. Khalili-Shirazi A, Quaratino S, Londei M, Summers L, Tayebi M, et al. (2005) Protein conformation significantly influences immune responses to prion protein. J Immunol 174: 3256-3263.
29. Oesch B, Westaway D, Walchli M, McKinley MP, Kent SB, et al. (1985) A cellular gene encodes scrapie PrP 27-30 protein. Cell 40: 735-746.
30. Regina A, Romero IA, Greenwood J, Adamson P, Bourre JM, et al. (1999) Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT. J Neurochem 73: 1954-1963.
31. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, et al. (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19: 1872-1874.
32. Borchelt DR, Scott M, Taraboulos A, Stahl N, Prusiner SB (1990) Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol 110: 743-752.
33. Beringue V, Mallinson G, Kaisar M, Tayebi M, Sattar Z, et al. (2003) Regional heterogeneity of cellular prion protein isoforms in the mouse brain. Brain 126: 2065-2073.
34. Chiesa R, Harris DA (2001) Prion diseases: what is the neurotoxic molecule? Neurobiol Dis 8: 743-763.
35. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, et al. (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379: 339-343.
36. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, et al. (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871-874.
37. Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, et al. (2000) Signal transduction through prion protein. Science 289: 1925-1928.
38. Mazzoni IE, Ledebur HC, Jr., Paramithiotis E, Cashman N (2005) Lymphoid signal transduction mechanisms linked to cellular prion protein. Biochem Cell Biol 83: 644-653.
39. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
40. Dumoulin M, Dobson CM (2004) Probing the origins, diagnosis and treatment of amyloid diseases using antibodies. Biochimie 86: 589-600.
41. Abulrob A, Sprong H, Van Bergen en Henegouwen P, Stanimirovic D (2005) The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 95: 1201-1214.
42. Muruganandam A, Tanha J, Narang S, Stanimirovic D (2002) Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J 16: 240-242.
43. Perrier V, Solassol J, Crozet C, Frobert Y, Mourton-Gilles C, et al. (2004) Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 89: 454-463.
44. Morrissey MP, Shakhnovich EI (1999) Evidence for the role of PrP(C) helix 1 in the hydrophilic seeding of prion aggregates. Proc Natl Acad Sci U S A 96: 11293-11298.
45. Speare JO, Rush TS, 3rd, Bloom ME, Caughey B (2003) The role of helix 1 aspartates and salt bridges in the stability and conversion of prion protein. J Biol Chem 278: 12522-12529.
46. Bendheim PE, Brown HR, Rudelli RD, Scala LJ, Goller NL, et al. (1992) Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 42: 149-156.
47. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, et al. (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356: 577-582.
48. Tayebi M, Enever P, Sattar Z, Collinge J, Hawke S (2004) Disease-associated prion protein elicits immunoglobulin M responses in vivo. Mol Med 10: 104-111.
49. Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, et al. (2001) Betalactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother 45: 2807-2812.